Grifols | GRFS - Sales Revenues


Grifols reported EUR2.34B in Sales Revenues for its fiscal quarter ending in March of 2026.





Sales Change Date
Alaunos Therapeutics USD 2K 2K Mar/2025
Arca Biopharma 0 0 Mar/2025
aTyr Pharma USD 110.08M 109.89M Dec/2025
Bio Path 0 0 Mar/2025
Brainstorm Cell Therapeutics 0 0 Mar/2025
Capricor Therapeutics USD 11.13M 8.87M Dec/2024
Cara Therapeutics USD 2.57M 1.11M Mar/2025
Esperion Therapeutics USD 168.45M 81.14M Dec/2025
GlaxoSmithKline GBP 8.62B 73M Dec/2025
Grifols EUR 2.34B 33.3M Mar/2026
Infinity Pharmaceuticals USD 583K 148K Jun/2023
Minerva Neurosciences USD 0 0 Sep/2024
Nektar Therapeutics USD 21.81M 2.32M Dec/2025
Sangamo BioSciences USD 356K 125K Jun/2024
TherapeuticsMD USD 234K 79K Jun/2024